|Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma|
|Qin Yazhen1; Lu Jin1; Bao Li1; Zhu Honghu1; Li Jinlan1; Li Lingdi1; Lai Yueyun1; Shi Hongxia1; Wang Yazhe1; Liu Yanrong1; Jiang Bin1; Huang Xiaojun1,2|
|关键词||multiple myeloma preferentially expressed antigen of melanoma expression bortezomib progression-free survival real-time quantitative polymerase chain reaction|
|刊名||CHINESE MEDICAL JOURNAL|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal|
|研究领域[WOS]||General & Internal Medicine|
|关键词[WOS]||STEM-CELL TRANSPLANTATION ; MINIMAL RESIDUAL DISEASE ; REFRACTORY MYELOMA ; PROGNOSTIC-FACTORS ; LEUKEMIA PATIENTS ; PRAME EXPRESSION ; STAGING SYSTEM ; MANAGEMENT ; PATTERNS ; THERAPY|
Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study.
Methods The transcript level of FRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real-time quantitative polymerase chain reaction, and the prognostic value of FRAME was determined through retrospective survival analysis. FRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or FRAME (+).
Results Sixty-two patients (62.0%) overexpressed FRAME. FRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression-free survival (PFS, n=96, all P > 0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. FRAME overexpression tended to be associated with a lower two-year PFS rate in patients treated with non-bortezomib-containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two-year PFS rate in patients with bortezomib-containing regimens (77.5% vs. 63.9%, P > 0.05). When the patients were categorized into PRAME (+) and FRAME () groups, treatment with bortezomib-containing regimens predicted a higher two-year PFS rate in FRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two-year PFS rate in FRAME () patients (63.9% vs. 76.9%, P > 0.05).
Conclusion FRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non-bortezonnib-containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.
|项目编号||Z111107067311070 ; 81170483 ; 81372535|
|资助机构||Beijing Municipal Science and Technology Program ; Nature Science Foundation of China|
|作者单位||1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China|
2.Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
|Qin Yazhen,Lu Jin,Bao Li,et al. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma[J]. CHINESE MEDICAL JOURNAL,2014,127(9):1666-1671.|
|APA||Qin Yazhen.,Lu Jin.,Bao Li.,Zhu Honghu.,Li Jinlan.,...&Huang Xiaojun.(2014).Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.CHINESE MEDICAL JOURNAL,127(9),1666-1671.|
|MLA||Qin Yazhen,et al."Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma".CHINESE MEDICAL JOURNAL 127.9(2014):1666-1671.|